CSL adding scalable stem cell gene therapy tech in $91m Calimmune buy – BioPharma-Reporter.com
BioPharma-Reporter.comCSL adding scalable stem cell gene therapy tech in $91m Calimmune buyBioPharma-Reporter.comAccording to spokeswoman Natalie de Vane, the acquisition is the first step into the cell and gene therapy space for CSL with the addition … Continue reading
